Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Distal Median Nerve Dysfunction and Carpal Tunnel Syndrome in People With Multiple Sclerosis Treated With Teriflunomide: An Electrodiagnostic Study Publisher Pubmed



Etemadifar M1 ; Ahmadi M2 ; Salari M3 ; Ansari B4 ; Sedaghat N5, 6
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Neurosurgery, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Functional Neurosurgery Research Center, Research Institute of Functional Neurosurgery, Shohada Tajrish Comprehensive Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  4. 4. Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  5. 5. Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran
  6. 6. Student Research Committee, Kashan University of Medical Sciences, Kashan, Iran

Source: Neurological Sciences Published:2025


Abstract

Background: Trials demonstrated an increased risk of distal median nerve dysfunction (DMND) and carpal tunnel syndrome (CTS) associated with teriflunomide in people with multiple (pwMS). Objective: To estimate the real-world prevalence of clinical CTS and electrodiagnostic DMND in teriflunomide-treated pwMS. Methods: Cross-sectional study on selected teriflunomide (WHOATC code: L04AK02)-treated, risk factor-free pwMS at the Isfahan MS clinic in 2022. CTS was diagnosed through history and physical examination, and DMND was diagnosed by nerve conduction studies (NCS). Outcome consisted of an ordinal scale of DMND as follows: no DMND, all values within normal limits; mild, sensory conduction velocity < 40 m/s with motor onset latency < 4.5ms; moderate, motor onset latency between 4.5–6.5ms; severe, motor onset latency > 6.5ms with amplitude > 0.2mV; and very severe, motor amplitude < 0.2mV. Results: 52 participants were included (median [range] duration of teriflunomide treatment: 3 [18] years); 5.8% were diagnosed with CTS, yet, 51.9% showed at least some evidence of DMND; of the 104 hands, 25% showed mild, 11.5% moderate, 2.9% severe, and none showed very severe DMND. Right hand side (aβ [SE]: 0.67 [0.26]; p = 0.01), duration of MS (aβ [SE]: -0.14 [0.05]; p = 0.01) and age (aβ [SE]: 0.06 [0.03]; p = 0.05) were associated with a worse grade of DMND, while the association of DMND grade with sex, EDSS score, duration of teriflunomide treatment, and prior DMT, were not confirmed (all p values > 0.05). Conclusion: A considerable proportion of teriflunomide-treated pwMS had DMND in at least one hand. The etiology, along its optimal management strategy, remains to be explored. © Fondazione Societa Italiana di Neurologia 2024.
3. Ultrasonographic Assessment of Carpal Tunnel Syndrome Severity: A Systematic Review and Meta-Analysis, American Journal of Physical Medicine and Rehabilitation (2019)
Experts (# of related papers)
Other Related Docs
13. Relationship Between Obsessive Compulsive Disorder and Carpal Tunnel Syndrome, Iranian Journal of Psychiatry and Behavioral Sciences (2010)
15. Treatment of Carpal Tunnel Syndrome: A Trial of Vitamin B6, Pakistan Journal of Medical Sciences (2012)
25. Hour Glass Constriction in Advanced Carpal Tunnel Syndrome, International Journal of Preventive Medicine (2013)